A
Ability Pharma
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
About Ability Pharma
Developer of medical therapies intended to focus on developing fully differentiated oral targeted anticancer compounds. The company's targeted therapies are drugs that kill cancer cells through the induction of robust cytotoxic autophagy, enabling doctors to improve the lives of the patients and cure them. Keywords: Pharmaceuticals and Biotechnology, Biopharmaceutical Company, Cancer Care, Cancer Drug Discovery, Cell Membrane, Gynecological Cancer, Healthcare Services, Therapeutic Strategy.
Source: Dealroom company dataAt a glance
- Founded
- 2009
- Headquarters
- Cerdanyola del Vallès, Spain
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Ability Pharma.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Capital Cell
European Innovation Council
US Food and Drug Administration
Series A7 investors entered at this stage
Inveready
Fitalent
EIC Fund
CTI Life Sciences- GOGESAMO Family Office
- IOIVAMOSA Family Office
CDTI Innvierte
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ability Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ability Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.